Atopic Dermatitis (AD)
Conditions
Interventions
Control group:Topical Desonide Cream?Calcineurin Inhibitors?Placebo Moisturizing Cream
Experimental group:Topical Desonide Cream?Calcineurin Inhibitors?MOMPICK Multi-Effect Nourishing Essence Cream
Sponsors
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 12 Years
Inclusion criteria
Inclusion criteria: 1.Meet the diagnostic criteria of Williams. 2.Age range from 3 months to 12 years, with no gender restrictions. 3.Disease severity is classified as mild to moderate. 4.Participants must not use other similar products on the affected skin area throughout the study. Guardians must ensure that no basic products (including skin care lotions, creams, emulsions, and glucocorticoids, etc.) are used on the affected skin area within 24 hours before the assessment. 5.The legal guardians of the participants must fully understand the purpose of the trial, use the medication as guided by the doctor throughout the study, undergo non-invasive skin physiological parameter measurements, voluntarily participate, and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Those with other skin diseases in the treatment area besides Atopic Dermatitis (AD). 2.Individuals with severe systemic diseases (such as cardiovascular, respiratory, digestive, nervous system, endocrine, and reproductive system diseases) with unstable conditions. 3.Those with impaired immune function (such as lymphoma, Acquired Immune Deficiency Syndrome (AIDS), etc.) or a history of malignant diseases. 4.Participants who are currently involved in other clinical studies or have participated in other clinical studies within the last 3 months, and those judged by the researcher to have poor compliance and are unable to complete the study as required. 5.Children who have received topical medication treatment within 7 days prior to enrollment, including calcineurin inhibitors, glucocorticoid preparations, and antihistamines. 6.Children who have undergone treatment with non-steroidal immunosuppressants or ultraviolet therapy, systemic glucocorticoids, and antihistamines within the last 4 weeks before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eczema Area and Severity Index;Visual Analogue Scale for Itch; | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigator's Global Assessment;Children's Dermatology Life Quality Index;Skin indicators (including moisture content);Transepidermal Water Loss; | — |
Countries
China
Contacts
Public ContactDeng Dan
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed